David A. Frey
Lawyers
Filters
RxSight $50 million follow-on offering
The stock is listed on the Nasdaq Global Market
ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
TD SYNNEX $502 million secondary offering
The shares are listed on the NYSE
Priveterra Acquisition initial business combination with AEON Biopharma
We are advising Priveterra on the transaction
Tenaya Therapeutics $75 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Snail $15 million IPO
We advised Snail on its IPO and Nasdaq listing
Akoya Biosciences $50 million at-the-market program
The common stock is listed on the Nasdaq Global Select Market
Nayax direct listing
The shares are listed on the Nasdaq Global Select Market
Tenaya Therapeutics $75 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
RxSight $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market